DaVita Inc. (NYSE:DVA) Shares Purchased by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC increased its position in shares of DaVita Inc. (NYSE:DVA) by 20.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,500 shares of the company’s stock after purchasing an additional 600 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in DaVita were worth $367,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hanseatic Management Services Inc. acquired a new position in DaVita during the third quarter worth $36,000. GAMMA Investing LLC acquired a new position in DaVita during the fourth quarter worth $60,000. FinTrust Capital Advisors LLC raised its holdings in DaVita by 242.3% during the third quarter. FinTrust Capital Advisors LLC now owns 712 shares of the company’s stock worth $67,000 after purchasing an additional 504 shares during the last quarter. Tacita Capital Inc purchased a new position in DaVita during the third quarter worth $118,000. Finally, Federated Hermes Inc. increased its position in DaVita by 1,284.4% during the third quarter. Federated Hermes Inc. now owns 1,246 shares of the company’s stock worth $118,000 after buying an additional 1,156 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other DaVita news, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the completion of the sale, the insider now owns 81,297 shares of the company’s stock, valued at $9,814,986.81. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total value of $1,362,438.05. Following the sale, the insider now directly owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The disclosure for this sale can be found here. Insiders sold a total of 134,540 shares of company stock valued at $16,551,071 over the last quarter. Company insiders own 1.40% of the company’s stock.

DaVita Price Performance

Shares of NYSE:DVA opened at $133.51 on Friday. The company has a market cap of $11.71 billion, a P/E ratio of 18.04, a P/E/G ratio of 1.19 and a beta of 1.04. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $141.54. The business has a fifty day simple moving average of $132.12 and a 200-day simple moving average of $110.60.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.53 by $0.34. The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.01 billion. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.11 earnings per share. Equities research analysts forecast that DaVita Inc. will post 9.23 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on DVA. StockNews.com raised DaVita from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Truist Financial raised their price target on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. Barclays began coverage on DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price target for the company. UBS Group raised their price target on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Finally, TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, DaVita presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.